MD1374G2 - Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică - Google Patents

Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică Download PDF

Info

Publication number
MD1374G2
MD1374G2 MD96-0296A MD960296A MD1374G2 MD 1374 G2 MD1374 G2 MD 1374G2 MD 960296 A MD960296 A MD 960296A MD 1374 G2 MD1374 G2 MD 1374G2
Authority
MD
Moldova
Prior art keywords
monoclonal
immunostimulatin
antibodies
obtaining
pharmaceutical composition
Prior art date
Application number
MD96-0296A
Other languages
English (en)
Russian (ru)
Other versions
MD1374F2 (ro
Inventor
Britta Hardy
Avraham Novogrodsky
Original Assignee
Mor Research Application Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Application Ltd filed Critical Mor Research Application Ltd
Publication of MD1374F2 publication Critical patent/MD1374F2/ro
Publication of MD1374G2 publication Critical patent/MD1374G2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)

Abstract

Invenţia se referă la medicină şi anume la imunoterapie.Esenţa invenţiei constă în aceea că anticorpul monoclonal imunostimulator sau fragmentul lui legând un antigen, careá legându-se cu celulele B limfoblastoide, induce proliferarea şi activarea limfocitelor sângelui periferic, asigură efectul antitumoral. Anticorpul propus se obţine prin imunizarea animalului cu un imunogen selectat din grupul constituit din celule B limfoblastoide, celule B limfoblastoide lizate sau preparate membranoase din ele, dezvoltarea ulterioară a reacţiei imune la animalul imunizat, extragerea limfocitelor B, creşterea, imortalizarea şi selectarea liniilor celulare, care secretează anticorpul revendicat. De asemenea, se declară linia celulară a hibridomului, depozitat în CNCM sub nr. 1-1397. Se propune o metodă de tratare a maladiilor, care include administrarea unei cantităţi eficiente de anticorp monoclonal propus. Se revendică o compoziţie farmaceutică, ce include în calitate de ingredient activ anticorpul monoclonal imunostimulator indicat. În plus, compoziţia farmaceutică poate suplimentar să conţină un agent care sporeşte activitatea limfocitelor citotoxice.Rezultatul este proliferarea şi activarea limfocitelor, asigurând efectul antitumoral.
MD96-0296A 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică MD1374G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies

Publications (2)

Publication Number Publication Date
MD1374F2 MD1374F2 (ro) 1999-12-31
MD1374G2 true MD1374G2 (ro) 2000-09-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică

Country Status (20)

Country Link
US (1) US5897862A (ro)
EP (1) EP0742795B1 (ro)
JP (1) JP3478398B2 (ro)
CN (1) CN1052733C (ro)
AT (1) ATE171461T1 (ro)
AU (1) AU693526B2 (ro)
CA (1) CA2182289C (ro)
DE (1) DE69504955T2 (ro)
DK (1) DK0742795T3 (ro)
EE (1) EE03285B1 (ro)
ES (1) ES2124533T3 (ro)
FI (1) FI963004A7 (ro)
IL (1) IL108501A (ro)
LT (1) LT4225B (ro)
LV (1) LV11624B (ro)
MD (1) MD1374G2 (ro)
MX (1) MX9603080A (ro)
NO (1) NO317020B1 (ro)
RU (1) RU2155190C2 (ro)
WO (1) WO1995020605A1 (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2145634C1 (ru) * 1998-03-12 2000-02-20 Булычева Татьяна Ивановна Штамм культивируемых клеток мышиной гибридомы, используемый для получения моноклональных антител к ядрышковому антигену, ассоциированному с клеточной пролиферацией
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
RU2192888C1 (ru) * 2001-02-15 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PT2242773T (pt) * 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3515944A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Clark, E. A, and Ledbetter, J.a. Amplification of the immune response by agonistic antibodies, Immunology Today. 1986, vol. 7, №9, p. 267-270; *
Ellenhorn, Joshua D. et al. In vivo administration of an anti-CD3 prevents malignant progressor tumor growth. Science (Washington, D.C.). 1988, vol. 242, p. 569-571; *
Gallinger, Steven et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice. Cancer Research. 1990, vol. 50, p. 2476-2480; *
Hardy, Britta et al. A monoclonal antibody to human B lymphoblastoid cells activates human and murine T lymphocytes. Cellular Immunology. 1989, vol. 118, p.22-29 *
Jenkins, Mars K. et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. The Journal of Immunology. 1991, vol.147, №8, p.2461-2466; *
Jung, Gundram et al. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. The Journal of Immunology. 1987, vol.139, №2, p. 639-644; *
Ledbetter, Jeffrey A. et al. Antibodies to Tp67 andTp44 augment and sustain proliferation responses of activated T cell. The Journal of Immunology. 1985, vol. 135, №4, p. 2331-2336; *
Meuer, Stefan C. et al. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin-2 dependent autocrine pathway. Proc. Natl. Acad. Sci. USA, 1984, vol. 81, p. 1509-1513; *
Moretta Alessandro et al. CD69-mediated pathway of lymphocyte activation: anti- CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor (/(. J. Exp. Med., 1991, vol. 174, p.1393-1398; *
Townsend, Sarah E. et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington, D.C.). 1993, vol. 259, p.368-370; *
Van Lier, R., et al. Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against region I and II of the CD2 antigen. Immunology, 1989, vol. 67, p. 333-338; *
Van Lier, Rene( A. W. et al. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies Eur. J. Immunol. 1998, vol. 18, p. 167-172; *
Van Wauwe, Jean P.,et al. OKT3: a monoclonal anti-human T lymphocyte antibody and potent mitogenic properties. The Journal of Immunology. 1980, vol. 124, №6, p. 2708-2713; *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase

Also Published As

Publication number Publication date
MD1374F2 (ro) 1999-12-31
NO963168D0 (no) 1996-07-29
FI963004A0 (fi) 1996-07-29
AU693526B2 (en) 1998-07-02
DE69504955D1 (de) 1998-10-29
IL108501A (en) 1998-10-30
JP3478398B2 (ja) 2003-12-15
US5897862A (en) 1999-04-27
EE03285B1 (et) 2000-08-15
LV11624B (en) 1997-06-20
WO1995020605A1 (en) 1995-08-03
CA2182289C (en) 2003-10-21
AU1868695A (en) 1995-08-15
NO963168L (no) 1996-09-27
EP0742795A1 (en) 1996-11-20
LV11624A (en) 1996-12-20
CN1052733C (zh) 2000-05-24
DK0742795T3 (da) 1999-06-14
LT96115A (en) 1997-05-26
CA2182289A1 (en) 1995-08-03
EP0742795B1 (en) 1998-09-23
FI963004L (fi) 1996-09-27
DE69504955T2 (de) 1999-05-27
CN1145077A (zh) 1997-03-12
NO317020B1 (no) 2004-07-26
ATE171461T1 (de) 1998-10-15
LT4225B (en) 1997-10-27
IL108501A0 (en) 1994-05-30
FI963004A7 (fi) 1996-09-27
MX9603080A (es) 1998-01-31
JPH09508390A (ja) 1997-08-26
RU2155190C2 (ru) 2000-08-27
ES2124533T3 (es) 1999-02-01

Similar Documents

Publication Publication Date Title
IL108501A0 (en) Novel antibodies and pharmaceutical compositions containing them
DE69709632D1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
GB9009548D0 (en) Chimeric antibody and method
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
IE890720L (en) Improvements relating to antigens
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
IL140138A0 (en) Specific antibodies of tie-2 ligands
EP1158004A3 (en) Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
ATE233102T1 (de) Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
EP0100904A3 (en) Improved protocol for the treatment of graft versus host disease
ES8802621A1 (es) Un procedimiento para preparar un anticuerpo monoclonal hu- mano
EP0194851A3 (en) Human tumor therapy
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
AU2070688A (en) Antigen recognized by mca 16-88
WO1999043815A3 (en) Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
WO1998023286A3 (en) Immunoconjugates comprising human monoclonal antibodies or fragments thereof for diagnostic and therapy

Legal Events

Date Code Title Description
PD99 Pending application